Toric implantable collamer lens offers good results

Article

Implanting the Toric Implantable Collamer Lens (TICL; STAAR Surgical) to correct various degrees of myopia and compound myopic astigmatism, produces predictable refractive results.

Implanting the Toric Implantable Collamer Lens (TICL; STAAR Surgical) to correct various degrees of myopia and compound myopic astigmatism, produces predictable refractive results, according to Daniel Elies from the Instut Oftalmologic Integral, Barcelona, Spain.

The TICL was implanted into 63 eyes of 36 patients with myopic compound astigmatism. The mean preoperative spherical equivalent (SE) was -10.58±3.41 D and the mean preoperative astigmatism was -3.59±1.38 D. The standard recommendations from the manufacturer regarding preoperative measurements, nomogram and implantation technique were followed.

Following implantation of the TICL, mean SE was -10.26 D (p<0.0001) and mean cylinder was -2.87 D (p<0.0001). Holladay analysis of astigmatism showed a large reduction.

At one-year follow-up, 82.5% of eyes had SE within ±0.50 D and 68.3± had an uncorrected visual acuity (UCVA) equal to or better than the preoperative best corrected visual acuity (BCVA). Approximately 60% of eyes gained at least one line of best spectacle corrected visual acuity (BSCVA). At two weeks postoperatively, four eyes had an intraocular pressure (IOP) over 21 mmHg due to steroids. Two eyes (of the same patient) developed adenoviric KCT and five eyes showed tilted IOL, one of which required repositioning.

Overall, Dr Elies concluded that the TICL offers predictable and effective refractive results.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.